Engineering a Cytolytic Human Protein Into a Novel Prostate Cancer Protoxin
Abstract
The principle investigator has made substantial progress in executing the statement of work outlined in the proposal. In addition he has fulfilled the requirements mandated by his training program to date. First, the PI obtained the human C5 cDNA and substituted a PSA substrate sequence in place of the wild type activation sequence. Modifications were implemented based on results from homology modeling. Next, PSA mediated cleavage was confirmed by mass spectrometry. Recombinant production of the confirmed PSA cleavable C5 mutant was scaled up by an adenovirus for in vitro assays. Purification of the recombinant protein is ongoing. Finally, the PI has begun working on a similar project that uses a different strategy to target prostate cancer cells in an androgen and growth-independent manner.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 31, 2010
- Accession Number
- ADA603042
Entities
People
- Michael L. Manning
Organizations
- Johns Hopkins University